Key Points
- Insider sale: Krishnaswamy Yeleswaram sold 20,225 shares on April 17 at an average price of $39.99 for about $808,798, trimming his stake by 7.58% to 246,426 shares valued near $9.85 million.
- Multiple April disposals: Yeleswaram also sold smaller blocks on April 8, 10, 13 and 14 at roughly $34.90–$35.08 per share, signaling a sequence of insider sales throughout the month.
- Company context: RAPP trades around $36.95 with a $1.77 billion market cap, recently reported a quarterly loss of $0.72 per share (missed estimates), yet the analyst consensus remains a Buy with an average target of $53.83.
Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider Krishnaswamy Yeleswaram sold 20,225 shares of Rapport Therapeutics stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $39.99, for a total value of $808,797.75. Following the completion of the transaction, the insider directly owned 246,426 shares in the company, valued at $9,854,575.74. This represents a 7.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Krishnaswamy Yeleswaram also recently made the following trade(s):
- On Tuesday, April 14th, Krishnaswamy Yeleswaram sold 10,200 shares of Rapport Therapeutics stock. The stock was sold at an average price of $35.08, for a total value of $357,816.00.
- On Monday, April 13th, Krishnaswamy Yeleswaram sold 9,165 shares of Rapport Therapeutics stock. The stock was sold at an average price of $34.97, for a total value of $320,500.05.
- On Friday, April 10th, Krishnaswamy Yeleswaram sold 500 shares of Rapport Therapeutics stock. The stock was sold at an average price of $34.98, for a total value of $17,490.00.
- On Wednesday, April 8th, Krishnaswamy Yeleswaram sold 360 shares of Rapport Therapeutics stock. The stock was sold at an average price of $34.90, for a total value of $12,564.00.
Rapport Therapeutics Trading Down 0.5%
Shares of RAPP opened at $36.95 on Wednesday. The business's 50-day moving average price is $30.70 and its 200 day moving average price is $28.68. The stock has a market capitalization of $1.77 billion, a P/E ratio of -12.92 and a beta of 1.09. Rapport Therapeutics, Inc. has a 1-year low of $7.73 and a 1-year high of $42.27.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last issued its quarterly earnings results on Tuesday, March 10th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.65) by ($0.07). On average, research analysts predict that Rapport Therapeutics, Inc. will post -3.1 earnings per share for the current year.
Hedge Funds Weigh In On Rapport Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of the business. Capital International Investors grew its stake in Rapport Therapeutics by 30.7% during the 3rd quarter. Capital International Investors now owns 3,402,529 shares of the company's stock valued at $101,055,000 after acquiring an additional 800,000 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Rapport Therapeutics by 23.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 3,001,879 shares of the company's stock valued at $91,077,000 after acquiring an additional 579,903 shares in the last quarter. Vanguard Group Inc. grew its stake in Rapport Therapeutics by 11.8% during the 4th quarter. Vanguard Group Inc. now owns 1,817,757 shares of the company's stock valued at $55,151,000 after acquiring an additional 191,219 shares in the last quarter. Baker BROS. Advisors LP grew its stake in Rapport Therapeutics by 181.2% during the 3rd quarter. Baker BROS. Advisors LP now owns 1,547,090 shares of the company's stock valued at $45,949,000 after acquiring an additional 997,000 shares in the last quarter. Finally, Alliancebernstein L.P. grew its stake in Rapport Therapeutics by 4.1% during the 2nd quarter. Alliancebernstein L.P. now owns 1,154,688 shares of the company's stock valued at $13,129,000 after acquiring an additional 45,063 shares in the last quarter.
Analyst Ratings Changes
RAPP has been the topic of a number of analyst reports. Raymond James Financial initiated coverage on Rapport Therapeutics in a research note on Friday, April 10th. They issued a "strong-buy" rating and a $66.00 price target on the stock. Wall Street Zen cut Rapport Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, March 14th. Truist Financial raised Rapport Therapeutics to a "strong-buy" rating in a research note on Wednesday, March 25th. TD Cowen reissued a "buy" rating on shares of Rapport Therapeutics in a research note on Monday, March 9th. Finally, BTIG Research lifted their target price on Rapport Therapeutics to $47.00 and gave the company a "buy" rating in a research note on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $53.83.
Check Out Our Latest Report on Rapport Therapeutics
Rapport Therapeutics Company Profile
(
Get Free Report)
Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.
Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
